Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Preparation of hydrophobic La2Mo2O9 ceramics with antibacterial and antiviral properties.

Matsumoto T, Sunada K, Nagai T, Isobe T, Matsushita S, Ishiguro H, Nakajima A.

J Hazard Mater. 2019 Jun 7;378:120610. doi: 10.1016/j.jhazmat.2019.05.003. [Epub ahead of print]

PMID:
31226590
2.

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.

Yasui M, Kawahara T, Izumi K, Yao M, Ishiguro Y, Ishiguro H, Uemura H, Miyoshi Y.

BMC Cancer. 2019 Apr 8;19(1):331. doi: 10.1186/s12885-019-5512-9.

3.

Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes.

Yokomizo Y, Kawahara T, Nagashima Y, Ishiguro H, Kato I, Yao M, Miyamoto H, Uemura H.

Int J Surg Case Rep. 2017;37:180-182. doi: 10.1016/j.ijscr.2017.06.047. Epub 2017 Jun 29. No abstract available.

4.

ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion.

Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H.

Oncotarget. 2016 Aug 16;7(33):53599-53610. doi: 10.18632/oncotarget.10679.

5.

Comparison of the antiviral effect of solid-state copper and silver compounds.

Minoshima M, Lu Y, Kimura T, Nakano R, Ishiguro H, Kubota Y, Hashimoto K, Sunada K.

J Hazard Mater. 2016 Jul 15;312:1-7. doi: 10.1016/j.jhazmat.2016.03.023. Epub 2016 Mar 9.

PMID:
27015373
6.

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.

Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, Makiyama K, Miyoshi Y, Miyamoto H, Yao M, Uemura H.

BMC Cancer. 2016 Feb 16;16:111. doi: 10.1186/s12885-016-2134-3.

7.

Phosphoproteome analysis demonstrates the potential role of THRAP3 phosphorylation in androgen-independent prostate cancer cell growth.

Ino Y, Arakawa N, Ishiguro H, Uemura H, Kubota Y, Hirano H, Toda T.

Proteomics. 2016 Apr;16(7):1069-78. doi: 10.1002/pmic.201500365.

PMID:
26841317
8.

Predicting the mineral composition of ureteral stone using non-contrast computed tomography.

Kawahara T, Miyamoto H, Ito H, Terao H, Kakizoe M, Kato Y, Ishiguro H, Uemura H, Yao M, Matsuzaki J.

Urolithiasis. 2016 Jun;44(3):231-9. doi: 10.1007/s00240-015-0823-z. Epub 2015 Oct 1.

PMID:
26427864
9.

Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H.

Mol Endocrinol. 2015 Oct;29(10):1486-97. doi: 10.1210/me.2015-1128. Epub 2015 Aug 31.

10.

Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.

Ishiguro H, Izumi K, Kashiwagi E, Zheng Y, Li Y, Kawahara T, Miyamoto H.

Am J Cancer Res. 2015 Jan 15;5(2):738-47. eCollection 2015.

11.

Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity.

Ito Y, Ishiguro H, Kobayashi N, Hasumi H, Watanabe M, Yao M, Uemura H.

Prostate. 2015 Jul 1;75(10):1009-19. doi: 10.1002/pros.22972. Epub 2015 Apr 27.

PMID:
25917126
12.

Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.

Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H.

Oncotarget. 2015 Jan 30;6(3):1582-93.

13.

The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.

Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Ishiguro H, Miyamoto H.

Prostate. 2015 May;75(6):573-84. doi: 10.1002/pros.22937. Epub 2015 Jan 28.

PMID:
25631176
14.

Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis.

Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H.

Mol Carcinog. 2016 Feb;55(2):161-9. doi: 10.1002/mc.22265. Epub 2015 Jan 15.

PMID:
25594762
15.

GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.

Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H.

Am J Cancer Res. 2014 Sep 6;4(5):461-73. eCollection 2014.

16.

Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression.

Ishiguro H, Kawahara T, Zheng Y, Netto GJ, Miyamoto H.

Am J Clin Pathol. 2014 Aug;142(2):157-64. doi: 10.1309/AJCPU8UCEZYG4WTV.

17.

Nonsteroidal anti-inflammatory drugs and prostatic diseases.

Ishiguro H, Kawahara T.

Biomed Res Int. 2014;2014:436123. doi: 10.1155/2014/436123. Epub 2014 May 12. Review.

18.

Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity.

Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H.

Cancer Chemother Pharmacol. 2014 Aug;74(2):249-55. doi: 10.1007/s00280-014-2496-7. Epub 2014 Jun 1.

PMID:
24880571
19.

Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Li Y, Ishiguro H, Kawahara T, Kashiwagi E, Izumi K, Miyamoto H.

Cancer Biol Ther. 2014 Apr;15(4):428-35. doi: 10.4161/cbt.27631. Epub 2014 Jan 21.

20.

Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death.

Sato A, Itcho N, Ishiguro H, Okamoto D, Kobayashi N, Kawai K, Kasai H, Kurioka D, Uemura H, Kubota Y, Watanabe M.

Int J Nanomedicine. 2013;8:3151-60. doi: 10.2147/IJN.S40766. Epub 2013 Aug 19.

Supplemental Content

Loading ...
Support Center